Aurinia begins voclosporin dosing in Phase III trial for LN
Canadian-based biopharmaceutical firm Aurinia Pharmaceuticals has begun dosing patients in the Phase III AURORA clinical trial of voclosporin to treat lupus nephritis (LN).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news